Migraine Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) - Estimates DelveInsight | Key Players - Satsuma, Biohaven Pharma, Allodynic, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly, Trevena

DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Migraine market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Migraine, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Migraine, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Migraine management.

Learn More About the Market Dynamics and Key Trends Shaping the Market Growth @ Migraine Market Outlook and Developments

Migraine: An Overview

Migraine is ranked globally as the seventh most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders. It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.

Migraine is classified by the nature of the attack and its frequency, as chronic and episodic migraine. Episodic migraine is characterized by those with migraine who have 0–14 headache days per month, while chronic migraine is characterized by 15 or more headache days per month.

Migraine treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.

Migraine Market Key Facts

• The total Migraine prevalent population in the 7MM was 118,491,000+ cases in 2021.
• According to Rebecca et al. (2019), migraine is common and occurs in about 12% of the US population overall, 18% of women, and 6% of men, each year.
• According to The Migraine Trust, migraine is the third most common disease globally, with an estimated global prevalence of 14.7% (that is around 1 in 7 people). Chronic migraine affects approximately 2% of the world's population.
• As per the study by Burch R. et al., (2018) stated that results from the National Health Interview Survey (NHIS) show that self-reported migraine and severe headache was reported by 15.3% of Americans overall, including 9.7% of men and 20.7% of women.

Learn More About the Major Trends and Developments @ Migraine Market Trends Analysis

Migraine Therapeutics Analysis

The current treatment outlook for migraines is multifaceted, focusing on both acute symptom relief and prevention of future attacks. Acute treatment typically involves medications such as triptans, NSAIDs, or anti-nausea drugs to alleviate pain, nausea, and other symptoms during an attack. However, the emphasis has also shifted towards preventive strategies for individuals with frequent or severe migraines. Preventive treatments include various medications like beta-blockers, antiepileptic drugs, and CGRP inhibitors, as well as lifestyle modifications to identify triggers and reduce their impact.

The primary revenue-generating components of the acute treatment market can be classified broadly into the following therapeutic classes, namely triptans, NSAIDs, analgesics/opioids, and DHE (dihydroergotamine) or ergot alkaloids. Triptans continue to dominate the overall acute treatment landscape generating the highest amount of revenue. Some of the major drugs (generics/branded) belonging to this class are eletriptan, almotriptan, sumatriptan, rizatriptan, zolmitriptan, and a few others.

Migraine Therapeutic Advancements and Emerging Treatments:

• Migraine Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.
• Migraine Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of migraines. Some of the emerging therapies in the pipeline include AXS-07: Axsome Therapeutics; STS-101: Satsuma Pharmaceuticals; Zavegepant: Biohaven Pharmaceuticals; TNX1900: Tonix Pharmaceuticals; INP104: Impel NeuroPharma, and others.

Delve Deeper into Key Players and Upcoming Treatments @ Migraine Therapeutic Pipeline Analysis

Migraine Market Growth Factors

The landscape of the Migraine market is experiencing a transformative shift, driven by a multitude of interconnected factors. Firstly, advancements in understanding the pathophysiology of migraines have led to the development of more targeted and effective treatments. The emergence of novel therapeutics, including CGRP (calcitonin gene-related peptide) monoclonal antibodies and neuromodulation devices specifically designed for migraine management, represents a significant leap forward in addressing this complex neurological disorder. Additionally, increased awareness and recognition of migraines as a debilitating condition have propelled the demand for better diagnostic tools and therapies. 

Moreover, the expanding pool of patients affected by migraines, coupled with a growing focus on personalized medicine, has incentivized pharmaceutical companies to invest in research and development for innovative treatment modalities. Furthermore, the incorporation of digital health technologies such as telemedicine and mobile applications for remote patient monitoring and support is reshaping the landscape of migraine care, enhancing accessibility and patient engagement. As these factors continue to converge, the migraine market is poised for substantial growth, with a promising trajectory toward providing more effective and personalized solutions for millions of individuals globally affected by this condition.

Migraine Market 

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Migraine. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Migraine market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Migraine drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Migraine Market Forecast

Migraine Epidemiology Assessment 

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Migraine epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Migraine epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Migraine Epidemiology, Segmented as -

• Total Prevalent Cases of Migraine in the 7MM [2019-2032]
• Prevalent Cases of Migraine by Severity (Episodic and Chronic Migraine) in the 7MM [2019-2032]
• Gender-specific Prevalence of Migraine in the 7MM [2019-2032]
• Diagnosed Cases of Migraine in the 7MM [2019-2032]

Migraine Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Migraine market during the study period. This analysis encompasses the assessment of drug uptake in the Migraine market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Migraine drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Migraine pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Migraine. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

For in-depth insights and detailed TOC, access the sample page @ Migraine Therapeutics Market Outlook and Forecast

Related Reports:

Migraine Epidemiology Forecast

Migraine Epidemiology Forecast report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Migraine Pipeline Insight

Migraine Pipeline Insight report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Contact Information:

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

 Connect with DelveInsight: LinkedIn | Facebook | Twitter